Biocogniv has raised $6.0M across 1 funding round.
Key people at Biocogniv.
Biocogniv was founded in 2019 by Artur Adib (Founder/CEO).
Biocogniv has raised $6.0M in total across 1 funding round.
Biocogniv was founded in 2019 by Artur Adib (Founder/CEO).
Biocogniv has raised $6.0M in total across 1 funding round.
Biocogniv's investors include 9Yards Capital, Coatue, Glasswing Ventures, Hatteras Venture Partners, High Alpha, Rebel Fund, Uncork Capital, Edith Harbaugh, Frederic Kerrest, John Abele, Sam Palmisano.
Key people at Biocogniv.
Biocogniv is a healthcare technology company that develops AI-based diagnostic solutions for hospitals, aiming to prevent avoidable deaths and reduce healthcare costs by detecting critical conditions earlier than conventional methods. Their flagship product, Sepsis aiMarker™, predicts sepsis up to 24 hours in advance using routine laboratory tests collected in emergency rooms, significantly improving emergency care outcomes. By leveraging large clinical databases and advanced AI models, Biocogniv provides real-world evidence without the high costs and risks associated with traditional clinical trials, positioning its technology to become a standard in acute care diagnostics[1][2].
Founded with a mission to combine laboratory medicine, cutting-edge AI, and evidence-based acute care, Biocogniv focuses on reducing preventable hospital deaths, morbidities, and healthcare costs. The company is led by Artur Adib, PhD, who has a strong background in computer science, biophysics, and engineering, including experience at Beta Technologies and Twitter. The leadership team also includes healthcare professionals like Alessandra Conner, OD, and a medical advisory board featuring prominent figures such as Dr. Frank Peacock and Dr. Myla Lai-Goldman, who bring deep expertise in emergency medicine and clinical diagnostics[3].
Biocogniv rides the growing trend of integrating AI with healthcare diagnostics, particularly in acute care settings where early detection can save lives and reduce costs. The convergence of large-scale clinical data and high-performance AI models is transforming medical diagnostics by enabling predictive insights that traditional methods cannot provide. The timing is critical as hospitals face increasing pressure to improve patient outcomes while managing costs. Biocogniv’s approach aligns with broader healthcare digitization and precision medicine trends, influencing how emergency medicine and hospital diagnostics evolve toward AI-driven, data-backed decision-making[2][3].
Biocogniv is poised to expand its impact by further validating and deploying its AI diagnostic tools across hospitals, potentially broadening beyond sepsis to other critical conditions. As regulatory acceptance of AI diagnostics grows and healthcare systems increasingly adopt predictive analytics, Biocogniv’s technology could become integral to standard clinical workflows. Future trends shaping their journey include advances in AI interpretability, integration with electronic health records, and expanding real-world evidence generation. Their influence is likely to grow as they demonstrate improved patient outcomes and cost savings, reinforcing the shift toward AI-enabled acute care[1][2][3].
Biocogniv has raised $6.0M across 1 funding round. Most recently, it raised $6.0M Seed in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $6.0M Seed | 9Yards Capital, Coatue, Glasswing Ventures, Hatteras Venture Partners, High Alpha, Rebel Fund, Uncork Capital, Edith Harbaugh, Frederic Kerrest, John Abele, Sam Palmisano |
